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Materials and methods
Patients and donors Acute graft-versus-host disease (aGVHD) remains a major complication following allogeneic bone marrow transplanBetween March 1994 and December 1995, 16 consecutive tation (BMT). Although the tissue damage is caused by patients who underwent HLA-matched related allogeneic donor-derived T lymphocytes that recognize antigenic dis-BMT for acute leukaemia at first complete remission were parities between donor and recipient, the lytic mechanism enrolled into this study. All patients were given a myeloleading to lesion formation has not been fully ascertained ablative therapy consisting of fractionated total body but probably involves several concurrent processes. These irradiation (TBI; 165 cGy twice daily for 4 consecutive include direct interactions between donor cytotoxic T lymdays (total 1320 cGy)) combined with cyclophosphamide phocytes (CTL) and host target cells, or more indirect (60 mg/kg once daily i.v. for 2 days (total dose 120 mg/kg)). Cyclosporin A and short-course methotrexate were used for GVHD prophylaxis to all patients. Diagnosis skin, gut and liver GVHD. All cases of aGVHD were USA). Freshly isolated PBL were labelled with monoclonal antibodies against the surface determinants CD3, CD45 (all pathologically proven by skin biopsies which were taken from the affected sites before any steroid therapy was FITC-conjugated), CD4, CD8, CD14, CD56, HLA-DR (all phycoerythrin-conjugated) from Becton Dickinson given. Because direct cytotoxic effects of chemoradiotherapy may be difficult to distinguish from the findings of (Mountain View, CA, USA). The FITC-conjugated Fas and CD28 were purchased from Immunotech (Marseille, aGVHD in the first 3 weeks after BMT, 12 we defined aGVHD when patients showed clinical and pathological France), and affinity-purified mouse anti-human FasL antibody was also used (Transduction Lab, Lexington, KY, findings including both epidermal basal-cell apoptosis with lymphoid infiltration and satellitosis. Also, serial biopsies USA In the aGVHD + and the control groups, the percentages of CD3 + and CD56 + cells were similar, but we observed a in serum-free medium (AIM V, GIBCO, Grand Island, NY, UPN = unique patient number; CMV = cytomegalovirus; ANC = absolute neutrophil count; aGVHD = acute graft-versus-host disease; Tx = treatment; M = male; F = female; AML = acute myeloid leukaemia; ALL = acute lymphoblastic leukaemia; R = recipient. Table 2 Absolute numbers of WBC, total lymphocytes and each patients with aGVHD (83.3 ± 5.1% vs 67.0 ± 2.2%, lymphocyte subset according to the occurrence of aGVHD P Ͻ 0.01) (Figure 1) .
Difference in the subpopulation of CD8 + cells (n = 6) (n = 10)
As mentioned above, an increase in the percentage of CD8 patients. Since HLA-DR has been usually suggested to indi-
Higher expression of Fas and FasL in patients with

